# Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder

> **NCT00659347** · PHASE2 · TERMINATED · sponsor: **DOV Pharmaceutical, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** DOV 21, 947
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00659347
- **Lead sponsor:** DOV Pharmaceutical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2008-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659347, "Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00659347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*